Logo-jcvtr

J Cardiovasc Thorac Res. 2021;13(2): 141-145. doi: 10.34172/jcvtr.2021.26
PMID: 34326968        PMCID: PMC8302897

Original Article

Prognostic significance of N-Terminal Pro-BNP in patients with COVID-19 pneumonia without previous history of heart failure

Murat Selçuk 1 * ORCID, Muhammed Keskin 1, Tufan Çınar 1, Nuran Günay 2, Selami Doğan 1, Vedat Çiçek 1, Şahhan Kılıç 1, Süha Asal 1, Samet Yavuz 1, Nurgül Keser 1, Ahmet L. Orhan 1

Cited by CrossRef: 12

1- O'Glasser A, Schenning K. COVID-19 in the perioperative setting: A review of the literature and the clinical landscape. Perioperative Care and Operating Room Management. 2022;28:100272 [Crossref]
2- Ogungbe O, Kumbe B, Fadodun O, Latha T, Meyer D, Asala A, Davidson P, Dennison Himmelfarb C, Post W, Commodore-Mensah Y. Subclinical myocardial injury, coagulopathy, and inflammation in COVID-19: A meta-analysis of 41,013 hospitalized patients. IJC Heart & Vasculature. 2022;40:100950 [Crossref]
3- Demirci Üçsular F, Karadeniz G, Polat G, Serçe Unat D, Ayrancı A, Yalnız E, Güldaval F. Can the Progression of COVID-19 Pneumonia be Predicted?. hamidiyemedj. 2022;3(2):124 [Crossref]
4- Al-kuraishy H, Al-Gareeb A, Alexiou A, Batiha G. Targeting and Modulation of the Natriuretic Peptide System in Covid-19: A Single or Double-Edged Effect?. CPPS. 2022;23(5):321 [Crossref]
5- Schmidt W, Pawlak-Buś K, Jóźwiak B, Leszczyński P. Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience. JCM. 2023;12(6):2429 [Crossref]
6- KARACA ÖZER P, AYDUK GOVDELI E. ASSOCIATION OF N-TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE LEVEL AND ECHOCARDIOGRAPHIC LEFT VENTRICULAR SYSTOLIC OR DIASTOLIC DYSFUNCTION IN NON-ACUTE DYSPNEA. Acta Med Nicomedia. 2023;6(1):1 [Crossref]
7- Maloberti A, Giannattasio C, Rebora P, Occhino G, Ughi N, Biolcati M, Gualini E, Rizzi J, Algeri M, Giani V, Rossetti C, Epis O, Molon G, Beltrame A, Bonfanti P, Valsecchi M, Genovesi S. Incident Atrial Fibrillation and In-Hospital Mortality in SARS-CoV-2 Patients. Biomedicines. 2022;10(8):1940 [Crossref]
8- Li P, Chen Q, Jovin I, Mankad A, Huizar J, Markley J, Bart B, Hattler B, Lesnefsky E, McFalls E. COVID-19 and myocardial injury: Targeting elevated biomarkers for potential novel therapies. Clinics. 2024;79:100473 [Crossref]
9- Chen C, Lin S, Shen C, Hsieh K, Cheng C. Biomarkers during COVID-19: Mechanisms of Change and Implications for Patient Outcomes. Diagnostics. 2022;12(2):509 [Crossref]
10- Ogungbe O, Kumbe B, Fadodun O, T L, Meyer D, Asala A, Davidson P, Dennison Himmelfarb C, Post W, Commodore-Mensah Y. Subclinical Myocardial Injury, Coagulopathy, and Inflammation in COVID-19: A Meta-Analysis of 41,013 Hospitalized Patients. SSRN Journal. 2021; [Crossref]
11- O’Donnell C, Ashland M, Vasti E, Lu Y, Chang A, Wang P, Daniels L, de Lemos J, Morrow D, Rodriguez F, O’Brien C. N‐Terminal Pro‐B‐Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID‐19 in a Nationwide Hospitalized Cohort. JAHA. 2021;10(24) [Crossref]
12- Paciorek M, Bieńkowski C, Kowalska J, Skrzat-Klapaczyńska A, Bednarska A, Krogulec D, Cholewińska G, Kowalski J, Podlasin R, Ropelewska-Łącka K, Wasilewski P, Boros P, Martusiewicz-Boros M, Pulik P, Pihowicz A, Horban A. Hospital Admission Factors Independently Affecting the Risk of Mortality of COVID-19 Patients. JCM. 2023;12(19):6264 [Crossref]
13- Çınar T, Şaylık F, Akbulut T, Asal S, Selçuk M, Çiçek V, Kılıç Ş, Orhan A. One-year outcomes of invasively managed acute coronary syndrome patients with COVID-19. Heart & Lung. 2022;52:159 [Crossref]
14- Sleem B, El Rassi C, Zareef R, Bitar F, Arabi M. NT-proBNP cardiac value in COVID-19: a focus on the paediatric population. Cardiol Young. 2024;34(5):959 [Crossref]